Evidence map›Paper›PMID 42905916›Full record

ReviewEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2026

Safety considerations and clinical monitoring during pulsed field ablation.

Pascal Defaye, Edward P Gerstenfeld, Melanie A Gunawardene, Jose L Merino, Jose M Guerra, Sandrine Venier, Savannah Bifulco, Andrea Sarkozy

Abstract readReview
In one paragraph

Review in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pascal DefayeArrhythmia Department/Cardiology Department, University Hospital of Grenoble Alpes, Avenue des Maquis du Grésivaudan, CS 10217, Grenoble 38043, France.ORCID 0000-0002-7183-4278
Edward P GerstenfeldElectrophysiology Section, Division of Cardiology, Department of Medicine, University of California San Francisco, 500 Parnassus Ave, San Francisco, CA 94143, USA.
Melanie A GunawardeneCCB, MVZ CCB Frankfurt und Main Taunus GbR, Markus Hospital, Wilhelm Epstein Strasse 4, Frankfurt am Main 60431, Germany.ORCID 0000-0001-7561-7185
Jose L MerinoArrhythmia and Robotic Electrophysiology Unit, La Paz University Hospital, IdiPaz, Madrid, Spain.ORCID 0000-0002-1737-1903
Jose M GuerraHospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), CIBERCV, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0001-5397-9177
Sandrine VenierArrhythmia Department/Cardiology Department, University Hospital of Grenoble Alpes, Avenue des Maquis du Grésivaudan, CS 10217, Grenoble 38043, France.ORCID 0000-0003-1129-5089
Savannah BifulcoDepartment of Electrophysiology, Boston Scientific, 4100 Hamline Ave N, St Paul, MN 55112, USA.ORCID 0000-0001-6679-6716
Andrea SarkozyHeart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium.ORCID 0000-0001-6327-0487

Funding

Boston Scientific
6 · The paper itself

Abstract

Pulsed field ablation (PFA) has emerged as a transformative technology in cardiac electrophysiology, offering a potentially superior safety profile compared with thermal ablation due to its non-thermal mechanism of irreversible electroporation. Clinical experience confirms a substantial reduction in traditional complications such as pulmonary vein stenosis, atrio-oesophageal fistula, and permanent phrenic nerve injury, though PFA introduces a distinct spectrum of physiologic effects requiring consideration. Coronary vasospasm is the most characteristic phenomenon, ranging from transient, subclinical constriction to rare ischaemic or arrhythmic events; mitigation relies on coronary anatomical awareness, optimized lesion placement, and prophylactic vasodilators. Haemolysis, caused by red blood cell electroporation, varies with catheter design and pulse burden and is typically mild, though high exposure and inadequate hydration may rarely lead to acute kidney injury. Silent cerebral lesions could result from procedural and/or energy-related factors, including gas formation, air ingress, catheter manipulation, and anticoagulation management, with uncertain long-term clinical impact but opportunities for technique-driven reduction. Interactions between PFA and cardiac implantable electronic devices are system- and context-dependent, with monopolar configurations and catheter-lead proximity influencing the risk of transient interference and rare permanent damage.

Indexed as

Atrial FibrillationIrreversible Electroporation TherapyMonitoring, IntraoperativeCoronary VasospasmHemolysisHumansPatient SafetyRisk FactorsTreatment OutcomeAcute kidney injuryAtrial fibrillation ablationCatheter designCIED interactionsCoronary artery spasmCoronary injuryCoronary spasmCoronary vasospasmElectromagnetic interferenceElectrophysiologyEmbolic effectsHaemolysisIrreversible ElectroporationMicrobubblesMicroembolismPhrenic nerve stunningProcedural complicationsPulsed field ablationRisk mitigationSafety profileSilent cerebral lesionsThromboembolic events

Identifiers

PMID42905916
PMCPMC13685794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.